Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived nucleated cells
- Development stage
- Discontinued
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
Autologous bone marrow-derived nucleated cells (BMCs) is an investigational cell therapy consisting of a patient's own unfractionated nucleated bone marrow cells, which include various stem and progenitor cell populations. The therapy involves harvesting bone marrow from the patient, followed by intracoronary infusion into the infarcted myocardium. The primary therapeutic objective is to promote cardiac repair, enhance left ventricular ejection fraction (LVEF), and mitigate adverse left ventricular remodeling following an acute ST-elevation myocardial infarction (STEMI). This approach was rigorously evaluated in the BOOST and BOOST-2 clinical trials, which were primarily led by academic investigators in Germany and Norway. However, the BOOST-2 trial, a randomized, double-blind, multicenter study, did not demonstrate a significant improvement in LVEF compared to placebo in patients receiving modern standard-of-care percutaneous coronary intervention (PCI) and pharmacological therapy.
- Other names
- autologous bone marrow-derived mononuclear cellsautologous bone marrow cellsbone marrow-derived nucleated cells
Beyond the preview
Go deeper on autologous bone marrow-derived nucleated cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived nucleated cells.